Herein, for the first time, we show that PRL-3 may play a role in drug resistance in AML and that modulation of PRL-3 expression plays a role in the synergistic antileukemic effect of co-treatment of ABT-869 and SAHA in FLT3-ITD positive AML. The gene discussed is PTP4A3; the disease is acute myeloid leukemia.